Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest early-stage breast cancer Stories

2008-09-08 09:00:52

WASHINGTON, Sept. 8 /PRNewswire/ -- Early clinical experience with the FDA cleared Axxent(R) Electronic Brachytherapy (eBx) System from Xoft demonstrates that the X-Ray-based, non-isotopic treatment is a viable option for adjuvant therapy for early-stage breast cancer. Initial data from this multi-center study was presented at the 2008 Breast Cancer Symposium here in Washington, DC. The phase IV study, "Early experience with an electronic brachytherapy technique for intracavitary...

2008-09-03 09:00:08

REDWOOD CITY, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Genomic Health, Inc. today announced the publication of positive results from a study indicating that the Oncotype DX(R) Recurrence Score(R) provides additional prognostic information beyond Adjuvant! Online (AO) for breast cancer patients with negative nodes or up to three positive nodes. The study, published in the September 1st issue of the Journal of Clinical Oncology, showed that the Recurrence Score result was a highly...

2007-07-25 18:25:33

FREMONT, Calif., July 25 /PRNewswire/ -- The American Medical Association (AMA) Common Procedural Terminology (CPT) Editorial Panel recently approved a CPT Code for the use of electronic brachytherapy, a novel form of high dose rate radiation therapy for the treatment of early stage breast cancer. According to Xoft, Inc., developer of the Axxent(R) Electronic Brachytherapy System, a proprietary cancer treatment platform, this decision is an important step in accelerating the adoption of the...

2007-04-25 09:23:02

MARIETTA, Ga., April 25 /PRNewswire/ -- WellStar Kennestone Hospital and The Breast Center in Marietta directed by Philip Z. Israel, M.D., announced today that it has completed treatment of the first breast cancer patient with a breakthrough new therapy for early stage breast cancer. Designed to help reduce recurrence of breast cancer, the Axxent(R) Electronic Brachytherapy System from Xoft, Inc., uses a miniaturized X-ray source that can deliver localized and targeted radiation treatment in...

2006-02-15 08:11:42

LONDON (Reuters) - A British woman with early-stage breast cancer lost a test case legal bid on Wednesday to force her health authority to pay for the potentially life-saving drug Herceptin, but vowed on Wednesday to continue her battle. High Court judge Justice Bean ruled that Swindon Primary Care Trust in Wiltshire, which had refused Ann Marie Rogers, 54, the costly drug treatment, need not pay for Herceptin, made by Switzerland's Roche. Summarising his decision, the judge said...

2006-02-06 09:42:58

LONDON (Reuters) - A woman with early-stage breast cancer went to the High Court on Monday in an attempt to force her local health authority to pay for the potentially life-saving drug Herceptin. Ann Marie Rogers, 54, was refused the drug after Swindon Primary Care Trust in Wiltshire said it would not fund the treatment, which costs around 20,000 pounds ($36,000) a year. Her counsel Ian Wise told the court the refusal had left Rogers feeling she had been given a "death sentence" and...

2005-10-05 10:51:05

LONDON (Reuters) - Women diagnosed with early stage breast cancer are to be tested to see if they are suitable for treatment with the drug Herceptin, made by Switzerland's Roche Holding AG, Britain said on Wednesday. The move could mean that the lives of 1,000 women a year in England could be saved -- the same number saved by the national breast screening program, the Department of Health (DOH) said. Recent research has shown Herceptin can help patients with early stage breast cancer...

2005-09-22 13:55:29

NEW YORK (Reuters Health) - The results of a survey of a large group of women with early-stage breast cancer suggest that many women are involved in the treatment decision-making process, and that greater patient involvement in treatment decisions is associated with a greater likelihood of undergoing mastectomy. There is general professional consensus that most women with early-stage breast cancer are good candidates for breast-conserving surgery. However, persistently high rates of...